Extrachromosomal DNA first attracted attention decades ago when researchers noticed strange, ring-shaped DNA fragments floating outside the chromosomes of tumor cells. Unlike chromosomal DNA, ecDNA is structurally independent, frequently circular and acentromeric, meaning it lacks the centromere structures that normally ensure chromosomes are distributed evenly during cell division. This absence has profound consequences. During mitosis, ecDNA molecules are inherited through noncanonical behaviors that allow unequal segregation between daughter cells, meaning one daughter cell can receive a windfall of oncogene copies while the other receives few or none. The review emphasizes that this non-Mendelian inheritance pattern also permits coordinated co-inheritance, in which multiple ecDNA species carrying different oncogenes and regulatory elements travel together through cell generations, allowing advantageous combinations of genes and regulatory states to persist and propagate within a tumor population.

The classical view of ecDNA centered on copy-number biology: more copies of an oncogene such as MYC or EGFR meant more messenger RNA and more oncogenic protein, fueling aggressive growth. The new synthesis argues that this framing misses the most consequential part of the story. ecDNA molecules carry not just genes but enhancers, the short DNA sequences that act as volume controls for gene expression. Because ecDNA is circular, enhancers that were once distant from their target genes on linear chromosomes can be brought into immediate physical proximity, rewiring enhancer-oncogene communication in ways that linear DNA cannot easily achieve. The review describes how ecDNA can hijack pre-existing enhancers, activate noncanonical regulatory elements that would normally remain silent, and thereby transform a raw genome rearrangement event into genuine epigenetic innovation.

At the physical level, ecDNA does not float passively in the nucleus. Advanced imaging and genomic mapping studies summarized in the review show that ecDNA molecules cluster together into transcriptionally active nuclear hubs, dense assemblies where multiple circular molecules and their target genes on chromosomes converge. These hubs behave like condensate-associated structures, membrane-less compartments that concentrate transcription machinery, transcription factors and co-activators at extraordinarily high local concentrations. The result is a hyperactive transcriptional factory that can drive oncogene expression to levels unattainable through ordinary chromosomal regulation. In this sense, ecDNA-positive tumor cells are not merely carrying extra genetic cargo; they are constructing an entirely new layer of nuclear architecture dedicated to amplifying and fine-tuning oncogenic signaling.

This architectural rewiring has direct consequences for chromatin itself. The review details how ecDNA reshapes chromatin accessibility, the degree to which DNA is physically open and available to transcription factors. ecDNA tends to maintain an unusually open chromatin state, rich in active histone marks, which keeps its passenger enhancers and promoters in a perpetually transcription-ready configuration. Because ecDNA hubs can also contact chromosomal targets, this openness can extend to the ordinary genome, altering which chromosomal genes are switched on or off. Through these mechanisms, ecDNA generates transcriptional plasticity, the capacity of a tumor cell to shift its gene-expression program rapidly in response to changing conditions, whether that condition is a drug, an immune attack or a change in nutrient supply.

That plasticity feeds directly into some of the most clinically feared phenomena in oncology. The review positions ecDNA as a key driver of intratumoral heterogeneity, the coexistence of genetically and epigenetically distinct cell populations within a single tumor. Because ecDNA segregates unequally during mitosis, daughter cells diverge quickly in oncogene dosage and regulatory state, generating a diverse portfolio of cellular phenotypes from a single founding lineage. This diversity provides abundant raw material for clonal evolution: when chemotherapy eliminates cells with one regulatory configuration, subpopulations with different ecDNA compositions and enhancer landscapes survive and repopulate the tumor. The same logic applies to metastatic adaptation, where disseminated cells must reprogram their transcriptional identity to colonize new tissues, and to therapeutic resistance, where ecDNA-mediated enhancer rewiring can rapidly upregulate drug targets or bypass inhibited pathways.

Yet the very features that make ecDNA so powerful for the tumor may also constitute its Achilles’ heel. The review highlights that the high transcriptional burden carried by ecDNA creates a form of genomic stress known as transcription-replication conflict. When the transcription machinery and the DNA replication machinery collide on the same stretch of DNA, the resulting collisions can stall replication forks and generate DNA damage. ecDNA-positive cells, with their extraordinarily high transcriptional output, may live permanently near the threshold of tolerable transcription-replication interference. This dependence suggests selective vulnerabilities that could be exploited therapeutically: drugs that further stress transcription or replication, or that disrupt the specialized regulatory architecture of ecDNA hubs, might preferentially harm ecDNA-rich tumors while sparing normal cells.

The authors also point to the dependence of ecDNA-positive tumors on the integrity of their nuclear hubs and condensates as a second class of vulnerability. If transcriptional output in these tumors relies on the physical coalescence of ecDNA molecules and their associated regulatory factors, then interventions that dissolve or destabilize those assemblies, for example by targeting condensate-forming proteins or the chromatin regulators that maintain open chromatin on ecDNA, could collapse the tumor’s oncogenic transcription program. Similarly, because ecDNA inheritance depends on noncanonical mitotic behaviors rather than centromeres, the machinery that distributes ecDNA during cell division represents another potential point of attack. None of these strategies has yet produced approved therapies, but the review frames them as a conceptual frontier for precision oncology, in which treatment decisions could one day be guided by mapping a tumor’s ecDNA complement and its regulatory architecture.

Perhaps the most significant contribution of the review is conceptual. By shifting the focus from copy-number biology to regulatory biology, the authors reframe ecDNA not as a passive amplifier of oncogenes but as an active platform for epigenetic reprogramming, a mobile, self-perpetuating module that converts structural genome chaos into functional transcriptional diversity. This reframing has implications for how scientists model tumor evolution, how pathologists assess tumor aggressiveness and how drug developers search for targets in the least stable, most adaptable corners of the cancer genome. As long-read sequencing, spatial genomics and chromatin mapping technologies mature, the ability to read a tumor’s ecDNA landscape may become as routine as today’s copy-number profiling, opening a window onto the epigenetic strategies that cancers use to survive everything medicine throws at them.

The review, published open access in Molecular Cancer, was supported by the Shandong Provincial Traditional Chinese Medicine Science and Technology Project and the Health Commission of Jiangxi Province. Its authors span institutions across China, including Nanchang University, Hunan University, Naval Medical University and Shandong First Medical University, reflecting the rapidly growing international effort to understand the nonchromosomal genome of cancer. What emerges from their synthesis is a picture of tumors that are not just collections of mutated genes but ecosystems of mobile regulatory elements, and of ecDNA as the engine that keeps those ecosystems adaptable, heterogeneous and, for now, one step ahead of treatment.

Subject of Research: The role of extrachromosomal DNA as a regulatory platform for epigenetic reprogramming in cancer

Article Title: Extrachromosomal DNA as a platform for epigenetic reprogramming in cancer

Article References: Liu, B.-X., Zhou, L., Lai, S., Han, X., Dai, X.-J., Liu, R., Wang, Y., Chen, D., Wei, J., Hu, H., Zu, W., Jiang, L., Chang, J., & Zha, L. (2026). Extrachromosomal DNA as a platform for epigenetic reprogramming in cancer. Molecular Cancer. https://doi.org/10.1186/s12943-026-02789-1

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02789-1

Keywords: extrachromosomal DNA, ecDNA, epigenetic reprogramming, chromatin accessibility, enhancer rewiring, transcriptional plasticity, tumor evolution, intratumoral heterogeneity, therapeutic resistance, nuclear hubs, precision oncology, Molecular Cancer

The phenomenon is called lineage infidelity, and it describes a form of cellular plasticity in which small-cell lung cancer cells transition between molecularly distinct states to evade both physiological pressures and therapeutic attack. Historically, the disease was viewed as a single, uniform neuroendocrine tumor. Modern genomic and transcriptomic profiling has dismantled that view entirely, revealing at least four major molecular subtypes defined by the dominant activity of key transcription factors: ASCL1 in the SCLC-A subtype, NEUROD1 in SCLC-N, POU2F3 in SCLC-P, and YAP1 marking a mesenchymal-like, non-neuroendocrine phenotype often called SCLC-Y. The status of YAP1 as a true lineage-defining factor remains debated among researchers, but its value as a marker of therapeutic escape is widely accepted.

Crucially, these states are not fixed. They represent fluid points along a phenotypic spectrum, allowing tumors to shift identities as conditions change. A tumor that begins as a highly neuroendocrine SCLC-A malignancy may transition toward a non-neuroendocrine or inflamed state when treatment targets its original vulnerabilities, effectively changing molecular camouflage mid-course. Single-cell RNA sequencing and genetically engineered mouse models have been instrumental in mapping these transitions, showing that they are governed less by new mutations and more by an epigenetic rheostat—a dynamic, reversible control system of gene expression built on chromatin remodeling and lineage-specific enhancers.

The mechanistic details are striking. The best-characterized switch occurs between the SCLC-A and SCLC-N states, both neuroendocrine but occupying distinct regulatory territories. Activation of NOTCH signaling induces the expression of HES1, which directly represses ASCL1, facilitating movement toward NEUROD1-positive or non-neuroendocrine phenotypes. In SCLC-A cells, ASCL1 acts as a pioneer factor keeping chromatin accessible at its target genes; when epigenetic co-factors such as LSD1 are perturbed, methylation marks at H3K4 and H3K9 change, effectively erasing the cell’s transcriptional memory and opening the door to alternative identities. MYC amplification can drive further progression, pushing cells from ASCL1-dominant states through NEUROD1-high states and ultimately toward YAP1-driven mesenchymal phenotypes.

Perhaps the most clinically consequential observation concerns the SCLC-I, or inflamed, subtype, which recent evidence suggests may be a common evolutionary endpoint for tumors treated with chemotherapy. This transition involves a global decrease in DNA methylation that activates endogenous retroviruses and triggers interferon signaling, supporting the shift toward an inflamed phenotype. Meanwhile, the tumor microenvironment supplies external cues that flip internal switches: hypoxia within the tumor core stabilizes HIF-1α, which downregulates neuroendocrine markers and promotes a migratory, mesenchymal-like state. Chemotherapy itself, beyond killing sensitive clones, induces stress responses that can push surviving cells into quiescent or variant states—raising the uncomfortable possibility that standard care may inadvertently steer tumors toward more recalcitrant identities.

But the review’s authors argue that this plasticity is not merely a survival strategy; it is also a weapon clinicians can turn against the tumor. Because every lineage transition opens a new window of vulnerability, they propose a ‘Push-and-Pull’ strategy of evolutionary steering. In the ‘Push’ phase, epigenetic modifiers such as LSD1 inhibitors destabilize the dominant lineage, inducing ASCL1-high neuroendocrine cells to lose their identity and transition toward a more inflamed or non-neuroendocrine state. In the ‘Pull’ phase, a second agent lethally targets the newly acquired state. If the Push produces an inflamed SCLC-I phenotype, the Pull would be immune checkpoint blockade, which is significantly more effective in that molecular context.

Subtype-specific vulnerabilities provide the ammunition for the Pull. Tumors transitioning from SCLC-A/N states toward SCLC-P develop a profound dependence on the DNA damage response, driven by replication stress from MYC or POU2F3 activity, making them hypersensitive to PARP and ATR inhibitors. Cells adopting a YAP1-high mesenchymal phenotype often upregulate the surface marker TROP2, and clinical trials are now investigating TROP2-targeted antibody-drug conjugates for patients whose tumors have undergone this transition—effectively converting a resistance mechanism into a delivery system for chemotherapy. Epigenetic agents such as HDAC or EZH2 inhibitors may even reset the chromatin landscape of resistant non-neuroendocrine cells, reverting them to a neuroendocrine state in which they regain sensitivity to original platinum regimens, a concept known as chemo-resensitization.

Implementing these strategies in the clinic is far from straightforward. Small-cell lung cancer rarely exists as a single pure subtype; high-resolution single-cell mapping shows that most clinical samples are composite tumors containing multiple subtypes in varying proportions. Treating the dominant clone often triggers explosive expansion of a pre-existing minor subclone, and distinguishing clonal selection from true transdifferentiation is essential, because the two demand different interventions. Real-time monitoring is therefore central to the entire framework: longitudinal analysis of circulating tumor DNA and circulating tumor cells can detect molecular signatures of a subtype switch—such as rising POU2F3 or YAP1 fragments, or shifts in subtype-specific DNA methylation patterns—months before imaging reveals tumor growth, allowing preemptive therapeutic pivots while disease burden remains low.

Pharmacological hurdles compound the challenge. HDAC inhibitors like vorinostat and EZH2 inhibitors like tazemetostat are FDA-approved for other malignancies, but their efficacy in small-cell lung cancer remains confined to early-phase trials. LSD1 inhibitors such as iadademstat have shown early promise but are not yet standard of care. Concurrent administration of epigenetic Push agents and cytotoxic Pull agents often produces prohibitive toxicities, including severe myelosuppression and gastrointestinal distress, because chromatin modifiers exert broad transcriptional effects. Sequential targeting mitigates toxicity but demands precise, validated liquid biopsy biomarkers that do not yet fully exist in clinical form. Overcoming these barriers, the authors suggest, will require more selective epigenetic tools such as PROTACs and dynamic trial designs that use ctDNA to trigger therapy switches before relapse becomes visible.

What emerges from this synthesis is a fundamentally new vision for treating one of medicine’s deadliest cancers. Rather than reacting to resistance after it appears, oncologists of the future may proactively direct tumor trajectories toward therapeutic dead ends—luring cancer cells into states where their acquired vulnerabilities become lethal traps. Preclinical platforms including genetically engineered mouse models, patient-derived xenografts, and organoids are already providing the testing grounds for such interventions, and precision immunotherapy approaches aim to extend the benefits of immune checkpoint inhibitors to cold tumors through epigenetic priming. If the capacity for change is the tumor’s greatest strength, the reviewers contend, it may also prove to be its ultimate undoing—transforming small-cell lung cancer from a recalcitrant malignancy into a disease that is manageable, and perhaps one day curable.

Subject of Research: Lineage infidelity and subtype plasticity driving chemoresistance in small-cell lung cancer

Article Title: Lineage infidelity in small-cell lung cancer: driving subtype transitions and acquired therapeutic vulnerabilities

Article References: Ajeh, I. J., Ikukpla’si, O. S. I., Bisoye, D. A., & Danraka, A. (2026). Lineage infidelity in small-cell lung cancer: driving subtype transitions and acquired therapeutic vulnerabilities. Clinical Cancer Bulletin, 5(1), Article 9. https://doi.org/10.1007/s44272-026-00061-7

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00061-7

Keywords: small-cell lung cancer, lineage infidelity, ASCL1, NEUROD1, POU2F3, YAP1, epigenetic reprogramming, tumor plasticity, chemoresistance, Push-and-Pull strategy, liquid biopsy, immune checkpoint blockade